Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Keros Therapeutics, Inc.KROS · Entity 6242 | Director | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Keros Therapeutics, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,958 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Sale · Disposed 2,625 · Balance 10,958 F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 150,047 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 150,047 F3: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 102,233 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 102,233 F4: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.
F4: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2021 Filed Mar 4, 2021 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,095 | $58.90 | $64,495.50 |
DisclosureSEC source: 0001209191-21-017549 · doc4.xml · nonDerivative · entry 17 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 646,232 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.39 to $59.37 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,377 | $57.93 | $137,699.61 |
DisclosureSEC source: 0001209191-21-017549 · doc4.xml · nonDerivative · entry 16 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 432,134 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.38 to $58.36 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 3,644 | $57.93 | $211,096.92 |
DisclosureSEC source: 0001209191-21-017549 · doc4.xml · nonDerivative · entry 15 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 647,327 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.38 to $58.36 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 30 | $67.60 | $2,028.00 |
DisclosureSEC source: 0001209191-21-017549 · doc4.xml · nonDerivative · entry 14 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 434,511 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 46 | $67.60 | $3,109.60 |
DisclosureSEC source: 0001209191-21-017549 · doc4.xml · nonDerivative · entry 13 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 650,971 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 516 | $66.04 | $34,076.64 |
DisclosureSEC source: 0001209191-21-017549 · doc4.xml · nonDerivative · entry 12 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 434,541 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.77 to $66.50 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 792 | $66.04 | $52,303.68 |
DisclosureSEC source: 0001209191-21-017549 · doc4.xml · nonDerivative · entry 11 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 651,017 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.77 to $66.50 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 479 | $65.28 | $31,269.12 |
DisclosureSEC source: 0001209191-21-017549 · doc4.xml · nonDerivative · entry 10 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 435,057 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.73 to $65.66 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 734 | $65.29 | $47,922.86 |
DisclosureSEC source: 0001209191-21-017549 · doc4.xml · nonDerivative · entry 9 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 651,809 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.73 to $65.66 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 406 | $64.09 | $26,020.54 |
DisclosureSEC source: 0001209191-21-017549 · doc4.xml · nonDerivative · entry 8 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 435,536 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.70 to $64.52 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 625 | $64.09 | $40,056.25 |
DisclosureSEC source: 0001209191-21-017549 · doc4.xml · nonDerivative · entry 7 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 652,543 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.70 to $64.52 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,169 | $63.22 | $73,904.18 |
DisclosureSEC source: 0001209191-21-017549 · doc4.xml · nonDerivative · entry 6 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 435,942 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.67 to $63.65 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,794 | $63.22 | $113,416.68 |
DisclosureSEC source: 0001209191-21-017549 · doc4.xml · nonDerivative · entry 5 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 653,168 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.67 to $63.65 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,473 | $62.11 | $91,488.03 |
DisclosureSEC source: 0001209191-21-017549 · doc4.xml · nonDerivative · entry 4 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 437,111 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.66 to $62.65 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,257 | $62.11 | $140,182.27 |
DisclosureSEC source: 0001209191-21-017549 · doc4.xml · nonDerivative · entry 3 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 654,962 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.66 to $62.65 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,050 | $61.33 | $64,396.50 |
DisclosureSEC source: 0001209191-21-017549 · doc4.xml · nonDerivative · entry 2 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 438,584 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.63 to $61.62 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14). F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,608 | $61.33 | $98,618.64 |
DisclosureSEC source: 0001209191-21-017549 · doc4.xml · nonDerivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 657,219 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.63 to $61.62 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14). F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 18, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 75 | $65.01 | $4,875.75 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 28 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 439,634 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.68 to $65.15 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 18, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 116 | $65.02 | $7,542.32 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 27 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 658,827 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.68 to $65.15 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 18, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 552 | $64.17 | $35,421.84 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 26 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 439,709 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.65 to $64.62 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 18, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 845 | $64.16 | $54,215.20 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 25 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 658,943 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.65 to $64.62 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 18, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 205 | $63.04 | $12,923.20 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 24 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 440,261 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.52 to $63.46 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 18, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 315 | $63.04 | $19,857.60 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 23 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 659,788 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.52 to $63.46 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 18, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 180 | $61.68 | $11,102.40 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 22 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 440,466 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.17 to $62.01 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 18, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 276 | $61.68 | $17,023.68 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 21 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 660,103 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.17 to $62.01 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 18, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 150 | $60.06 | $9,009.00 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 20 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 440,646 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.63 to $60.52 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 18, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 230 | $60.06 | $13,813.80 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 19 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 660,379 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.63 to $60.52 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,705 | $62.72 | $106,937.60 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 18 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 440,796 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.25 to $63.19 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,613 | $62.72 | $163,887.36 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 17 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 660,609 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.25 to $63.19 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,201 | $61.80 | $74,221.80 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 16 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 442,501 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.25 to $62.23 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,841 | $61.80 | $113,773.80 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 15 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 663,222 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.25 to $62.23 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 764 | $60.66 | $46,344.24 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 14 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 443,702 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.25 to $61.24 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,173 | $60.66 | $71,154.18 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 13 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 665,063 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.25 to $61.24 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,249 | $59.96 | $134,850.04 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 12 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 444,466 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.24 to $60.23 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 3,449 | $59.96 | $206,802.04 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 11 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 666,236 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.24 to $60.23 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 421 | $58.74 | $24,729.54 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 10 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 446,715 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.24 to $59.22 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 645 | $58.74 | $37,887.30 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 9 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 669,685 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.24 to $59.22 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 90 | $60.92 | $5,482.80 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 8 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 447,136 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.90 to $60.97 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 138 | $60.92 | $8,406.96 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 7 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 670,330 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.90 to $60.97 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,609 | $60.23 | $157,140.07 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 6 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 447,226 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.86 to $60.70 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 3,999 | $60.23 | $240,859.77 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 5 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 670,468 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.86 to $60.70 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 661 | $59.34 | $39,223.74 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 4 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 449,835 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.86 to $59.82 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,014 | $59.34 | $60,170.76 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 3 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 674,467 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.86 to $59.82 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 434 | $58.48 | $25,380.32 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 2 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 450,496 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.84 to $58.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16) and (17). F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 667 | $58.48 | $39,006.16 |
DisclosureSEC source: 0001209191-21-012098 · doc4.xml · nonDerivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 675,481 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.84 to $58.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16) and (17). F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 30 | $63.85 | $1,915.50 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 22 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 450,930 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 46 | $63.85 | $2,937.10 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 21 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 676,148 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 531 | $63.14 | $33,527.34 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 20 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 450,960 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.75 to $63.73 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 814 | $63.14 | $51,395.96 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 19 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 676,194 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.75 to $63.73 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 641 | $62.52 | $40,075.32 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 18 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 451,491 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.20 to $62.68 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.